BCOP Updates 2024: Updates in the Management of Ovarian and Endometrial Cancers
In recent years, there have been significant changes in the treatment landscape for ovarian and endometrial cancers. This presentation will focus on practice-changing updates, as well as future areas of interest. In ovarian cancer, the role of PARP inhibitors has shifted based on long-term follow-up data. We will review updated efficacy and safety outcomes, as well as current indications for PARP inhibitors. Approval of the novel therapy mirvetuximab soravtansine-gynx has provided a valuable line of therapy in ovarian cancer in the recurrent platinum-resistant setting. We will review its mechanism of action, dosing, side effects, and monitoring, as well as the efficacy and safety data which led to its approval. In endometrial cancer, recent data has led to the approval of immunotherapy in combination with chemotherapy; the role of immunotherapy in recurrent endometrial cancer and the results of NRG-GY018 will be reviewed, as well as long-term follow-up from the KEYNOTE-775 study. Lastly, the presentation will discuss ongoing studies in risk stratification and the role of molecular testing in endometrial cancer, which may in the future lead to a more tailored approach to adjuvant therapy.
BCOP Updates 2024: Updates in the Management of Ovarian and Endometrial Cancers
Author: Christine Barrett, PharmD, BCOP
UAN#: 0465-0000-24-091-H01-P
Learning Objectives:
- Define the current role of PARP inhibitors in ovarian cancer based on long-term follow-up data and approved indications
- Describe the role of mirvetuximab soravtansine-gynx in ovarian cancer, including a review of its mechanism of action, dosing, and side effects, as well as efficacy and safety data
- Summarize ongoing clinical trials and future areas of interest in ovarian cancer
- Describe the role of immunotherapy in advanced or recurrent endometrial cancer
- Discuss the role of molecular testing and current evidence for risk stratification in endometrial cancer
- Identify notable ongoing studies in the treatment of endometrial cancer
Get it Now!
Knowledge Course for Pharmacist
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
![acpe-bps-logos](/media/images/acpe-bps-logos.width-500.png)
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.